Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Lexaria Bioscience Corp. Common Stock

LEXX

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $4.13 – $4.46
Volume 17,518
Market cap $9M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$9.29M
Price / earnings
—
Price / book
1.96×
Price / sales
47.89×
EV / sales
29.97×
EV / EBITDA
-0.76×

Profitability

Earnings per share
-$3.67
Return on assets
-161.71%
Return on equity
-163.18%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
10.6×
Quick ratio
10.6×
Cash ratio
9.06×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$7.47M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LEXX, quarterly periods
Line itemQ3 FY2026 May 31, 2026Q2 FY2026 Feb 28, 2026Q1 FY2026 Nov 30, 2025Q4 FY2025 Aug 31, 2025Q3 FY2025 May 31, 2025Q2 FY2025 Feb 28, 2025Q1 FY2025 Nov 30, 2024Q4 FY2024 Aug 31, 2024
Revenue$0$20K$0$174K$174K$174K$183.92K$84K
Cost of revenue$0$0$0$0$0$0$2.72K$0
Gross profit$0$20K$0$174K$174K$174K$181.2K$84K
Selling, general and administrative$1.02M$996.52K$902.29K$980.48K$1.21M$1.24M$918.69K$1.32M
Research and development$970.83K$475.39K$671.34K$1.88M$2.72M$1.69M$1.95M$967.21K
Total operating expenses$1.99M$1.47M$1.57M$2.86M$3.92M$2.93M$2.87M$2.29M
Operating income-$1.99M-$1.45M-$1.57M-$2.69M-$3.75M-$2.75M-$2.69M-$2.2M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$1.99M-$1.45M-$1.6M-$2.7M-$3.79M-$2.72M-$2.71M-$2.19M
Income taxes$14$2.6K$1.79K$0$0$0$0$0
Net income-$1.99M-$1.45M-$1.6M-$2.7M-$3.79M-$2.72M-$2.71M-$2.19M
Net income attributable to common shareholders-$1.99M-$1.45M-$1.6M-$2.7M-$3.79M-$2.71M-$2.7M-$2.18M
EBITDA-$1.97M-$1.43M-$1.56M-$2.67M-$3.72M-$2.75M-$2.66M-$2.19M
Basic earnings per share-$1.20-$0.90-$1.05-$2.07-$3.15-$2.25-$2.40-$2.07
Diluted earnings per share-$1.20-$0.90-$1.05-$2.07-$3.15-$2.25-$2.40-$2.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Whoosh Wellness Launches Physician-Guided Telehealth Platform Offering Oral-First Wellness Protocols and Prescribed Microdosing Programs

Whoosh Wellness, a new premium telehealth platform, launched with a focus on oral-first delivery formats for wellness protocols including semaglutide, tirzepatide, and other compounds. The platform differentiates itself through physician-prescribed microdosing approaches designed to minimize side effects while maintaining efficacy, targeting health-conscious professionals and longevity-focused consumers seeking remote physician-guided care.

Benzinga

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance. Asana reported quarterly losses of 4 cents per share which beat the analyst consensus estimate of losses of 10 cents by 60%. Quarterly sales came in at $171.1 million, beating the analyst consensus estimate of $167.676 million by 2.04%. The company expects fiscal year 2025 adjusted losses of between 22 cents and 19 cents per share, versus the losses of 22 cents estimate and fiscal year revenues of between $716 million and $722 million, versus the $724.75 estimate. Asana shares dipped 11% to $16.72 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers ClearOne, Inc. (NASDAQ: CLRO) rose 168.4% to $2.4299. ClearOne announced a special one-time cash dividend of 50 cents per share. Regulus Therapeutics Inc. (NASDAQ: RGLS) climbed 74.3% to $2.4050 after the company announced topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The company announced an oversubscribed $100 million private placement of equity. Assure Holdings Corp. (NASDAQ: IONM) gained 49% to $0.4880. Assure Holdings entered into an agreement to sell certain of its assets to MPOWERHealth for up to $4.5 million. Ranpak Holdings Corp. (NASDAQ: PACK) shares gained 40.1% to $6.12 after the company reported better-than-expected fourth-quarter revenue results and issued FY24 guidance. Also, Baird maintained an Outperform rating on the stock and raised its price target from $5 to $7. Singularity Future Technology Ltd. (NASDAQ: SGLY) climbed 37.6% to $4.3321 after gaining over 6% on Monday. Li-Cycle Holdings Corp. (NASDAQ: LICY) gained 27.4% to $0.5111 after the company entered an agreement to issue a senior secured convertible note in an aggregate principal amount of $75 million to an affiliate of Glencore. Nukkleus Inc. (NASDAQ: NUKK) shares rose 22.5% to $1.41 after surging over 43% on Monday. ATRenew Inc. (NYSE: RERE) gained 17.7% to $1.4003 after the company ...

GlobeNewswire Inc.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

GlobeNewswire Inc.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 3, 20261-for-15reverse split